I was reviewing the old UBS (?) research report which had a PT...

I was reviewing the old UBS (?) research report which had a PT of $3.30 base, $1.30 downside etc.

Looking at the report it projected $40.6m in revenue and $63.9m in ARR and NPAT of -$26.1m. FY22 report isn't released yet so NPAT isn't available yet but just ACTUAL revenue came in at $36m (12% lower) and ARR at $59m (8% lower) than what was projected. Is it lower? Yes. Is it completely off the mark? No.

Even if you use the original downside share price target of $1.30 it is still 52% HIGHER than what it is at the moment. As always DYOR. I'm doing mine.